AbbVie Completes $10.9 Billion Acquisition of Apogee Therapeutics

Key Facts

1AbbVie announced the completion of its acquisition of Apogee Therapeutics to bolster its immunology pipeline in dermatology and respiratory diseases.

2AbbVie reaffirmed its previously issued 2026 full-year adjusted diluted EPS guidance range of $13.87 - $14.07.

3The acquisition includes zumilokibart for atopic dermatitis and APG273 for asthma treatment.

In a move reflecting the strategy of major pharmaceutical firms to expand their therapeutic portfolios, AbbVie has announced the completion of its acquisition of Apogee Therapeutics. This transaction aims to bolster the company's pipeline in dermatology and respiratory diseases, integrating key assets such as zumilokibart for atopic dermatitis and APG273 for asthma treatment. The acquisition positions AbbVie to strengthen its global immunology footprint through the integration of advanced clinical candidates.

The acquisition was finalized for $135.11 per share in cash, representing a total equity value of approximately $10.9 billion according to the transaction terms. Alongside the closing, AbbVie reaffirmed its previously issued full-year 2026 adjusted diluted EPS guidance range of $13.87 to $14.07. This reaffirmation signals management's confidence in absorbing the acquisition costs while maintaining its established financial targets for shareholders.

Traders are monitoring ABBV stock, which stood at $261.7 at close on September 2, 2026, after trading within a range of $257.7 to $262.97 during that session per market data. While the upcoming economic calendar shows no immediate sector-specific catalysts, focus remains on future quarterly earnings reports to assess the financial impact of integrating Apogee's assets. Investors will also watch for clinical trial updates regarding the newly acquired immunology programs.